Wenwen Tian

Wenwen Tian

Auto-generated profile, based on publicly available information

Wenwen Tian

State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou 510060 P. R. China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JXJindong Xie
Jindong Xie
JZJunsheng Zhang
Junsheng Zhang
WTWenwen Tian
Wenwen Tian
YZYutian Zou
Yutian Zou
Yuhui TangYuhui Tang
Yuhui Tang
XXXiaoming Xie
Xiaoming Xie
The forkhead box O (FOXO) transcription factors (TFs) family are frequently mutated, deleted, or amplified in various human cancers, making them attractive candidates for therapy. However, their roles in pan-cancer remain unclear. Here, we evaluated the expression, prognostic value, mutation, methylation, and clinical features of four FOXO family genes (FOXO1, FOXO3, FOXO4, and FOXO6) in 33 types of cancers based on the Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) databases. We used a single sample gene set enrichment analysis (ssGSEA) algorithm to establish a novel index called “FOXOs score”. Moreover, we investigated the association between the FOXOs score and tumor microenvironment (TME), the responses to multiple treatments, along with drug resistance. We found that the FOXO family genes participated in tumor progression and were related to the prognosis in various types of cancer. We calculated the FOXOs score and found that it was significantly correlated with multiple malignant pathways in pan-cancer, including Wnt/beta-catenin signaling, TGF-beta signaling, and hedgehog signaling. In addition, the FOXOs score was also associated with multiple immune-related characteristics. Furthermore, the FOXOs score was sensitive for predicting the efficacy of diverse treatments in multiple cancers, especially immunotherapy. In conclusion, FOXO family genes were vital in pan-cancer and were strongly correlated with the TME. A high FOXOs score indicated an excellent immune-activated TME and sensitivity to multiple treatments. Hence, the FOXOs score might potentially be used as a biomarker in patients with a tumor.

5 January 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
LWLinyu Wu
Linyu Wu
SHShanshan Huang
Shanshan Huang
WTWenwen Tian
Wenwen Tian
PLPeng Liu
Peng Liu
YXYi Xie
Yi Xie
XXXinhua Xie
Xinhua Xie
Breast cancer is the second leading cause of death in women worldwide, with triple-negative breast cancer (TNBC) having the worst prognosis. Although there are numerous studies on TNBC, there is no effective treatment for it, and it is still a major problem today. Studies on PIWI-interacting RNAs (piRNAs) are increasing and investigating the mechanism of piRNAs in the proliferation and metastasis of TNBC may lead to new potential treatment targets. Here, we identified a novel piRNA, piR-YBX1, which was downregulated in TNBC compared to matched normal breast tissue. Overexpression of piR-YBX1 significantly inhibited the proliferation, migration, invasion ability of TNBC cells both in vivo and in vitro. Mechanistically, piR-YBX1 could bind directly to mRNA of Y-box binding protein 1 (YBX1) and overexpression of piR-YBX1 downregulated YBX1 in both mRNA and protein levels, while the function of piR-YBX1 could be partly rescued by overexpression of YBX1. In addition, YBX1 could bind to RAF1 which is the key molecule in the MAPK signaling pathway, and overexpression of piR-YBX1 inhibited the p-MEK and p-ERK1/2, which can be reverted by YBX1. In conclusion, our findings discovered that the piR-YBX1/YBX1/MAPK axis suppresses the proliferation and metastasis of TNBC and therefore piR-YBX1 has the potential to be an effective therapeutic agent for breast cancer.

29 July 2024 in Advanced Science
Verified
Journal Article
Open access
WTWenwen Tian
Wenwen Tian
LZLewei Zhu
Lewei Zhu
YLYongzhou Luo
Yongzhou Luo
YTYuhui Tang
Yuhui Tang
QTQingjian Tan
Qingjian Tan
FYFeng Ye
Feng Ye
Aggressive triple‐negative breast cancer (TNBC) still lacks approved targeted therapies, requiring more exploration of its underlying mechanisms. Previous studies have suggested a potential role of SAT1 (Spermidine/Spermine N1‐acetyltransferase 1) in cancer, which needs to be further elucidated in breast cancer. In this study, highly expressed SAT1 in TNBC signified worse patient prognoses. And SAT1 knockdown effectively inhibited the proliferation and migration abilities of TNBC cells in vitro and in vivo. In terms of mechanism, the transcription factor JUN enhanced SAT1 transcriptional activity by binding to its promoter region. Then, SAT1 protein in the cytoplasm engaged in directly binding with YBX1 for sustaining YBX1 protein stability via deubiquitylation mediated by the E3 ligase HERC5. Further, SAT1 was found to suppress autophagy remarkably via stabilization of mTOR mRNA with the accumulation of YBX1‐mediated methyl‐5‐cytosine (m5C) modification. These findings proved that SAT1 drives TNBC progression through the SAT1/YBX1/mTOR axis, which may provide a potential candidate for targeted therapy in advanced TNBC.

1 December 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
WTWenwen Tian
Wenwen Tian
Yuhui TangYuhui Tang
Yuhui Tang
YLYongzhou Luo
Yongzhou Luo
JXJindong Xie
Jindong Xie
Shaoquan ZhengShaoquan Zheng
Shaoquan Zheng
XXXiaoming Xie
Xiaoming Xie
Aurora-A kinase interacting protein 1 (AURKAIP1) has been proved to take an intermediary role in cancer by functioning as a negative regulator of Aurora-A kinase. However, it remains unclear whether and how AURKAIP1 itself would directly engage in regulating malignancies. The expression levels of AURKAIP1 were detected in triple negative breast cancer (TNBC) by immunohistochemistry and western blots. The CCK8, colony formation assays and nude mouse model were conducted to determine cell proliferation whereas transwell and wound healing assays were performed to observe cell migration. The interaction of AURKAIP1 and DEAD-box helicase 5 (DDX5) were verified through co-immunoprecipitation and successively western blots. From the results, we found that AURKAIP1 was explicitly upregulated in TNBC, which was positively associated with tumor size, lymph node metastases, pathological stage and unfavorable prognosis. AURKAIP1 silencing markedly inhibited TNBC cell proliferation and migration in vitro and in vivo. AURKAIP1 directly interacted with and stabilized DDX5 protein by preventing ubiquitination and degradation, and DDX5 overexpression successfully reversed proliferation inhibition induced by knockdown of AURKAIP1. Consequently, AURKAIP1 silencing suppressed the activity of Wnt/β-catenin signaling in a DDX5-dependent manner. Our study may primarily disclose the molecular mechanism by which AURKAIP1/DDX5/β-catenin axis modulated TNBC progression, indicating that AURKAIP1 might serve as a therapeutic target as well as a TNBC-specific biomarker for prognosis.

19 February 2020 in Research Square
Verified
Preprint
Open access
PDF file
WTWenwen Tian
Wenwen Tian
XXXinhua Xie
Xinhua Xie
YKYanan Kong
Yanan Kong
PLPeng Liu
Peng Liu
WTWeige Tan
Weige Tan
XXXiaoming Xie
Xiaoming Xie
Background For primary neuroendocrine carcinoma of breast was a very rare subtype in breast cancers, its prognosis was still controversial and there was no independent standard for its treatment. The purpose of our retrospective study was to construct a nomogram to predict the overall survival (OS) of patients with neuroendocrine carcinoma of the breast. Methods 150 patients of training cohort were collected from Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2003 and 2015, and 93 patients of verification cohort were enrolled from Sun Yat-sen University Cancer Center (Guangzhou, China) diagnosed between 2004 and 2018. The nomogram was constructed uniting three significantly risk factors of overall survival identified by univariate and multivariate analysis and then validated using receiver operating characteristic (ROC) curves for discrimination, calibration plots and the decision curves analysis (DCA). Results Age, N stage and PR status were closely and significantly related to overall survival in patients with breast neuroendocrine carcinoma. The C-index of nomogram in the training and verification cohorts are 0.775 (95% CI, 0.784 to 0.615) and 0.760 (95% CI, 0.705 to 0.800) respectively. Calibration plots of practical and predicted possibility for the nomogram demonstrated that the predictive 5-year overall survival rate was in accordance with the actual overall survival probability in both sets. Moreover, the decision curves (DCA) also expressed pretty clinical benefit of the nomogram across a range of high-risk threshold. Conclusion This novel population-based nomogram may help with treatment decisions in patients with neuroendocrine carcinoma of the breast (NEBC).